Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients

Table 1 Basal demographic and biochemistry criteria of all patients (mean ± SD)

Criteria	Total
Number	102
Age (yr)	32.5 ± 7.3
Sex (male/female)	90/12
BMI	25.6 ± 2.7
Baseline Hb (g/dL)	14.07 ± 1.1
plt (× 103/μL)	238.5 ± 62.7
WBCs (× 103/μL)	6.3 ± 1.4
ALT > ULN, n (%)	78 (76.5)
Creatinine level (mg/dL)	0.91 ± 0.44
Baseline HCV RNA (log IU/mL)	5.4 ± 0.7
Metavir fibrosis stage, n (%)
F1	69 (67.7)
F2	30 (29.4)
F3	3 (2.9)
Grade of inflammation, n (%)
A1	64 (62.7)
A2	33 (29.4)
A3	5 (5.4)
PEG IFN, n (%) (dose)
α2a	72 (70.6) (180 μg/wk)
α2b	30 (29.4) (1.5 μg/kg per week)
Ribavirin dose (mg/kg per day)	12.5 (10-15)
HCV genotype (G), n (%)	G4, 62 (60.8); G1, 40 (39.2)

Hb: Hemoglobin; BMI: Body mass index; plt: Platelet; WBCs: White blood cells; ALT: Alanine aminotransferase; ULN: Upper limit of normal of ALT = 12 IU/L; HCV: Hepatitis C virus; PEG-IFN: Pegylated interferon.

Table 2 Clinical and laboratory data according to rs1127354 inosine triphosphate pyrophosphatase genotypes (mean ± SD)

Criteria	CC	CA + AA	P value
Number, n (%)	93 (91.2)	9 (8.8)
Age (yr)	32.3 ± 7.3	34.4 ± 7.7	0.457
Sex (male/female)	82/11	8/1
BMI	25.4 ± 2.8	26.8 ± 1.6	0.046
Baseline Hb (g/dL)	14 ± 1.2	14.3 ± 1.03	0.441
plt (× 103/μL)	233.2 ± 62.1	292.2 ± 74.3	0.046
WBCs (× 103/μL)	6.2 ± 1.5	6.8 ± 1.1	0.172
ALT > ULN, n (%)	71 (76.3)	7 (77.7)	> 0.99
Creatinine level (mg/dL)	0.9 ± 0.46	0.98 ± 0.22	0.349
Baseline HCV RNA (log IU/mL)	5.46 ± 0.7	5.4 ± 0.8	> 0.99

Hb: Hemoglobin; BMI: Body mass index; plt: Platelet; WBCs: White blood cells; ALT: Alanine aminotransferase; ULN: Upper limit of normal of ALT = 12 IU/L; HCV: Hepatitis C virus.

Table 3 Logistic regression analysis during the first 12 wk of combination therapy

Variable	Univariate		Multivariate
	OR (95%CI)	P value	OR (95%CI)	P value
Sex (female)	0.49 (0.1-2.4)	0.386	4.7 (0.9-26.4)	0.123
Age (≥ 40 yr)	0.66 (0.24-1.8)	0.421	1.02 (0.9-1.1)	0.462
BMI ( ≤ 24)	2.03 (0.82-5.01)	0.124	1.2 (1-1.5)	0.068
Baseline Hb (< 15)	0.14 (0.04-0.49)	0.002	0.8 (0.5-1.2)	0.610
Baseline plt (< 200)	0.26 (0.1-0.65)	0.004	0.9 (0.9-1)	0.073
ITPA genotype (CC)	6.36 (1.24-32.41)	0.025	0.4 (0.04-4.08)	0.671
RBV dose ≥ 80%	0.08 (0.01-0.3)	0.0009	0.87 (0.82-0.92)	0.00002

OR: Odds ratio; BMI: Body mass index; Hb: Hemoglobin; plt: Platelet; ITPA: Inosine triphosphate pyrophosphatase; RBV: Ribavirin.

Table 4 The average ribavirin dose during 2 different time-points among inosine triphosphate pyrophosphatase CC and non CC genotypes

	During first 12 wk			12-48 wk of treatment
	Total	CC	CA + AA	Total	CC	CA + AA
No. of patients	102	93	9	91	82	9
RBV dose (mg/wk), mean ± SD	947 ± 151.4	936 ± 148.3	1059 ± 144.1	943 ± 153.2	930.5 ± 149.6	1059 ± 144.1
P value		0.035			0.029

RBV: Ribavirin.